# 510k Summary

# Dimension Vista® Ammonia $\boldsymbol { \mathsf { F l e x } } ^ { \otimes }$ reagent cartridge (AMM) Dimension Vista® Chem 3 Calibrator (CHEM 3 CAL)

This summary of 510(k) safety and effectiveness information is submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

# 1. 510(k) Number

Applicant: Rose T. Marinelli Siemens Healthcare Diagnostics, Inc. P.O. Box 6101, Newark, DE 19714-6101 Office Number: 302-631-8805; Fax Number: 302-631-6299

3. Date: November 28, 2012

4. Proprietary and Established Names:

Dimension Vista® Ammonia Flex® reagent cartridge, (AMM) Dimension Vista® Chem 3 Calibrator (CHEM 3 CAL)

5. Regulatory Information:

Ammonia (AMM) $F l e x ^ { \otimes }$ reagent cartridge

Regulation section: 21 CFR 862.1065 Enzymatic Method, Ammonia   
Classification: Class 1   
Product Code: JIF   
Panel: Clinical Chemistry

Chemistry 3 Calibrator (CHEM 3 CAL)

Regulation section: 21 CFR 862.1150 Calibrator, Secondary   
Classification: Class II   
Product Code: JIX   
Panel: Clinical Chemistry

# Predicate Devices:

The predicate device used to demonstrate substantial equivalence to the Dimension® Ammonia (AMM) Flex® reagent cartridge is the Dimension® Ammonia (AMON) previously cleared under k863840.

The predicate device used to demonstrate substantial equivalence to the Dimension Vista® Chemistry 3 Calibrator (CHEM 3 CAL) is the Dimension Vista® Chemistry 3 Calibrator (CHEM 3 CAL) previously cleared under k062334.

# 7. Device Description:

The Dimension Vista® Ammonia assay (AMM) is an enzymatic method that uses glutamate dehydrogenase (GLDH) and a stabilized NADPH analog. Ammonia reacts with α-ketoglutarate and reduced cofactor to form L-glutamate and the cofactor. The reaction is catalyzed by glutamate dehydrogenase. The decrease in absorbance due to the oxidation of the reduced cofactor is monitored at 340/700 nm and is proportional to the ammonia concentration.

The Dimension Vista® Ammonia (AMM) $\mathsf { F l e x } ^ { \otimes }$ reagent cartridge is an in vitro diagnostic device that consists of prepackaged reagents in a plastic cartridge for use on the Dimension Vista® System. Flex® reagent cartridges hold reagents for a test method. Each Dimension Vista® Flex has twelve wells.

# Reagents

<table><tr><td>Wells}$ 1 - 12</td><td>Form Liquid</td><td>Ingredient a-ketoglutarate GLDH</td><td>Concentrationb.c 10 mmol/L ≥ 24 KU/L 0.2 mmol/L</td><td>Source Microbial</td><td></td></tr><tr><td colspan="8"></td></tr></table>

a. Wells are numbered consecutively from the wide end of the cartridge. b. Nominal value per well in a cartridge. C. Contain buffers, stabilizers and preservatives.

Reagent preparations are performed automatically on the instrument. A barcode label on the cartridge identifies the test method, lot number, expiration date and maximum number of tests for which the cartridge can supply reagent.

The Dimension Vista® Chemistry 3 Calibrator (CHEM 3 CAL) is a two level, liquid calibrator. It is packaged as a kit of six vials with $2 . 5 \mathsf { m L }$ per vial. The product is a multi-analyte, aqueous product containing ammonium bicarbonate, sodium carbonate and ethyl alcohol. This product is sold separately from the $F l e x ^ { \otimes }$ reagent cartridge.

# Intended Use:

The AMM method is an in vitro diagnostic test for the quantitative measurement of ammonia in human plasma on the Dimension Vista® System. Ammonia measurements are used in the diagnosis and treatment of severe liver disorders such as cirrhosis, hepatitis and Reye's syndrome.

The CHEM 3 CAL is an in vitro diagnostic product for the calibration of Ammonia (AMM), Carbon Dioxide (CO2) and Ethyl Alcohol (ETOH) methods on the Dimension Vista® System

# 9. Indication(s) for Use:

The AMM method is an in vitro diagnostic test for the quantitative measurement of ammonia in human plasma on the Dimension Vista® System. Ammonia measurements are used in the diagnosis and treatment of severe liver disorders such as cirrhosis, hepatitis and Reye's syndrome.

The CHEM 3 CAL is an in vitro diagnostic product for the calibration of Ammonia (AMM), Carbon Dioxide (CO2) and Ethyl Alcohol (ETOH) methods on the Dimension Vista® System

# 10. Substantial Equivalence Information:

Both the Dimension Vista® Ammonia $\mathsf { F i e x } ^ { \otimes }$ reagent cartridge (AMM) assay and the predicate Dimension Ammonia $\mathsf { F l e x } ^ { \otimes }$ reagent cartridge (AMON) assay employ prepackaged reagents for use on automated clinical chemistry test systems. A comparison of the similarities and differences between the devices is provided in the following tables.

Note: Siemens has decided to offer our customers both conventional units and Systéme International d'Unités (Sl units) in the Instructions for Use (IFU). The predicate, Dimension® Ammonia (AMON) assay results are reported in SI Units only. All data supplied in Appendix C will include both conventional units and Sl Units for ease of review. Raw data was collected from the instruments in Sl units and the conventional units were calculated using the following equation: $\mathsf { \Pi } \mu \mathsf { g } / \mathsf { d L } \times 0 . 5 8 7 = [ \mathsf { \mu m o l / L } ]$

Similarities for Dimension Vista® AMM assay:

Differences for Dimension Vista® AMM assay:   

<table><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=1>New Device : Dimension Vista®Ammonia Flex® reagentcartridge (AMM)</td><td rowspan=1 colspan=1>Predicate: DimensionAmmonia Flex reagentcartridge (AMON) k863840</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>The AMM method is an in vitrodiagnostic test for the quantitativemeasurement of ammonia inhuman plasma on the DimensionVista® System. Ammoniameasurements are used in thediagnosis and treatment of severeliver disorders such as cirrhosis,hepatitis and Reye&#x27;s syndrome.</td><td rowspan=1 colspan=1>The AMON method used on theDimension® clinical chemistrysystem is an in vitro diagnostictest intended for the quantitativedetermination of ammonia inhuman plasma.</td></tr><tr><td rowspan=1 colspan=1>Format</td><td rowspan=1 colspan=1>Prepackaged for use on anautomated system.</td><td rowspan=1 colspan=1>Prepackaged for use on anautomated system.</td></tr><tr><td rowspan=1 colspan=1>Measurement</td><td rowspan=1 colspan=1>Bichromatic Rate</td><td rowspan=1 colspan=1>Bichromatic Rate</td></tr></table>

<table><tr><td colspan="1" rowspan="1">Feature</td><td colspan="1" rowspan="1">New Device: Dimension VistaAmmonia Flex® reagentcartridge (AMM)</td><td colspan="1" rowspan="1">Predicate: DimensionAmmonia Flex® reagentcartridge (AMON) k863840</td></tr><tr><td colspan="1" rowspan="1">MeasuringRange</td><td colspan="1" rowspan="1">17-1277 µg/dL [10 - 750 µmol/L]</td><td colspan="1" rowspan="1">0 - 1000 μmol/L</td></tr><tr><td colspan="1" rowspan="1">Sample Type</td><td colspan="1" rowspan="1">Plasma (Lithium Heparin andEDTA)</td><td colspan="1" rowspan="1">Plasma (EDTA, Lithium Heparin,Sodium Fluoride</td></tr><tr><td colspan="1" rowspan="1">Reagent Form</td><td colspan="1" rowspan="1">Liquid</td><td colspan="1" rowspan="1">Tablet</td></tr><tr><td colspan="1" rowspan="1">Units</td><td colspan="1" rowspan="1">µg/dL and µmol/L</td><td colspan="1" rowspan="1">[μmol/L</td></tr><tr><td colspan="1" rowspan="1">Sample Size</td><td colspan="1" rowspan="1">20 μL</td><td colspan="1" rowspan="1">53 μL</td></tr><tr><td colspan="1" rowspan="1">Feature</td><td colspan="1" rowspan="1">New Device: Dimension Vista®Chem 3 Calibrator (CHEM 3CAL) (KC130A)</td><td colspan="1" rowspan="1">Predicate: Dimension Vista®Chem 3 Calibrator (CHEM 3CAL) (KC130)</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">The CHEM 3 CAL is an in vitrodiagnostic product for thecalibration of Carbon Dioxide(CO2) and Ethyl Alcohol (ETOH)methods on the Dimension VistaSystem.</td><td colspan="1" rowspan="1">The CHEM 3 CAL is an in vitrodiagnostic product for thecalibration of Carbon Dioxide(CO2) and Ethyl Alcohol (ETOH)methods on the Dimension VistaSystem.</td></tr><tr><td colspan="1" rowspan="1">Preparation</td><td colspan="1" rowspan="1">Liquid: Ready to use</td><td colspan="1" rowspan="1">Liquid: Ready to use</td></tr><tr><td colspan="1" rowspan="1">Storage</td><td colspan="1" rowspan="1">2-8°C</td><td colspan="1" rowspan="1">2-8°C</td></tr><tr><td colspan="1" rowspan="1">Traceability</td><td colspan="1" rowspan="1">AMM - ASC Grade AmmoniumSulfateECO2 - NIST SRM 351ETOH - USP Grade EthylAlcohol</td><td colspan="1" rowspan="1">AMM - ASC Grade AmmoniumSulfateECO2 - NIST SRM 351ETOH - USP Grade EthyI Alcohol</td></tr><tr><td colspan="1" rowspan="1">Matrix</td><td colspan="1" rowspan="1">Aqueous product containing ethylalcohol, ammonium bicarbonateand sodium carbonate.</td><td colspan="1" rowspan="1">Aqueous product containing ethylalcohol, ammonium bicarbonateand sodium carbonate.</td></tr><tr><td colspan="1" rowspan="1">TargetConcentrations</td><td colspan="1" rowspan="1">EC02 - CAL A - 0 mmol/LCALB - 50 mmol/LETOH - CAL A - 0 mg/dLCAL B - 315 mg/dL</td><td colspan="1" rowspan="1">EC02 - CAL A - 0 mmol/LCAL B - 50 mmol/LETOH - CAL A - 0 mg/dLCAL B - 315 mg/dL</td></tr></table>

Differences for Dimension Vista® CHEM 3 CAL

<table><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=1>New Device: Dimension VistaChem 3 Calibrator (CHEM 3CAL) (KC130A)</td><td rowspan=1 colspan=1>Predicate: Dimension VistaChem 3 Calibrator (CHEM 3CAL) (KC130)</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>The CHEM 3 CAL is an in vitrodiagnostic product for thecalibration of Ammonia (AMMmethod on the Dimension Vista®System.</td><td rowspan=1 colspan=1>The CHEM 3 CAL is an in vitrodiagnostic product for thecalibration of Ammonia (AMON),method on the Dimension Vista®System.</td></tr><tr><td rowspan=1 colspan=1>TargetConcentrationsfor AMM</td><td rowspan=1 colspan=1>Calibrator A: 0 µg/dL[µmol/L]Calibrator B: 1405 µg/dL[825 μmol/L]</td><td rowspan=1 colspan=1>+Calibrator A: 0 µmol/LCalibrator B: 1000 pmol/L</td></tr><tr><td rowspan=1 colspan=1>Units</td><td rowspan=1 colspan=1>μg/dL and µmol/L</td><td rowspan=1 colspan=1>μmol/L</td></tr></table>

# 11. Standard/Guidance Document Reference:

Evaluation of Precision Performance of Quantitative Measurement in Methods; Approved Guideline (EP5-A2)   
•Evaluation of the Linearity of Quantitative Measurement Procedures; A Statistical Approach; Approved Guideline (EP6-A)   
Interference Testing in Clinical Chemistry; Approved Guideline (EP7-A2)   
Method Comparison and Bias Estimation Using Patient Samples; Approved Guideline (EP9-A2)   
Protocols for Determination of Limits of Detection and Quantitation; Approved Guideline (EP17-A)   
Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory; Approved Guideline (C28-A3)   
Evaluation of Stability of In-Vitro Diagnostic Reagents; Approved Guideline (EP25-A)

# 12. Performance Characteristics

The following data represent typical performance for the Dimension Vista® System and were collected on a Dimension Vista® 1500 System.

# Method Comparison

Split sample comparison between the Dimension Vista® Ammonia (AMM) assay and the Dimension Vista® Ammonia (AMON) assay gave the following correlation statistics, when tested with patient samples:

Dimension Vista® Ammonia (AMM) vs. Predicate   

<table><tr><td rowspan=1 colspan=1>DimensionVista</td><td rowspan=1 colspan=1>Predicate</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>Interceptμg/dL [μmol/L]</td><td rowspan=1 colspan=1>CorrelationCoefficient (r)</td><td rowspan=1 colspan=1>n</td></tr><tr><td rowspan=1 colspan=1>AMM</td><td rowspan=1 colspan=1>DimensionAMON</td><td rowspan=1 colspan=1>1.03</td><td rowspan=1 colspan=1>13.6 µg/dL[8.0 μmol/L]</td><td rowspan=1 colspan=1>0.993</td><td rowspan=1 colspan=1>100</td></tr></table>

# Plasma Equivalency Comparison

To demonstrate equivalency between lithium heparin plasma and EDTA plasma for Dimension Vista® AMM assay, comparison testing of 49 fresh matched lithium heparin and EDTA plasma samples were tested on the Dimension Vista® System and gave the following linear regression statistics:

Plasma Equivalency Comparison Data   

<table><tr><td rowspan=1 colspan=1>LithiumHeparin vs.</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>Interceptµg/dL [μmol/L]</td><td rowspan=1 colspan=1>CorrelationCoefficient (r)</td><td rowspan=1 colspan=1>n</td></tr><tr><td rowspan=1 colspan=1>EDTA</td><td rowspan=1 colspan=1>0.96</td><td rowspan=1 colspan=1>3.3 [2.0]</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>49</td></tr></table>

# Reference Interval (Expected Values)

The reference interval of $1 9 - 5 4 \mu { \mathfrak { g } } / { \mathsf { d L } }$ [11 - 32 pmol/L] for the predicate was validated for use with the Dimension Vista® Ammonia (AMM) assay by transference following CLSI C28-A3 Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory - Approved Guideline - Third Edition. The literature reference used was the Textbook of Clinical Chemistry by NW Tietz; WB Saunders Co., Philadelphia, PA; pages 1487-1488.

Expected Values: 19 - 54 µg/dL [11 - 32 µmol/L]

# Precision

Precision testing was performed in accordance with CLSI EP5-A2 Evaluation of Precision Performance of Quantitative Measurement Methods; Approved Guideline - Second Edition. Samples consisted of three levels of Liquicheck ™ Ethanol/Ammonia control. Testing was performed over 20 days, two separate runs with two test samples for each test material. Analysis of variance (ANOVA) was used to evaluate the data consistent with the recommendations of EP5-A2. The data are summarized in the following Dimension® Ammonia (AMM) Summary Table:

<table><tr><td colspan="2">Mean</td><td rowspan="2">Standard Deviation (%CV) Repeatability Within-Lab µg/dL [μmol/L] %CV</td><td rowspan="2"></td></tr><tr><td>Material</td><td>μg/dL [ μmol/L]</td></tr><tr><td>Liquichek ™m Ethanol/Ammonia control</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td></tr><tr><td>Level 1</td><td>44 [26]</td><td>2.7[1.6] (6.1)</td><td>3.3[1.9] (7.5)</td></tr><tr><td>Level 2</td><td>186 [109]</td><td>2.3 [1.4] (1.2)</td><td>3.2 [1.9] (1.7)</td></tr><tr><td>Level 3</td><td>563 [331]</td><td>3.5 [2.1] (0.6)</td><td>5.0 [2.91 (0.9)</td></tr></table>

# Linearity

The linear range was determined according to CLSI EP-6A, Evaluation of the Linearity of Quantitative Measurement Procedures; A Statistical Approach; Approved Guideline. Based on the results of this testing and the Limit of Detection testing on the Dimension Vista® System, the analytical measurement range was determined to be 17 - 1277 µg/dL [10 - 750 µmol/L].

![](images/155b35bdfb15f23d9b7348c1729213f253e40e04ec51513f170eae8e3e76d083.jpg)

# Analytical Specificity/Interferences

# Interfering Substances

The AMM assay was evaluated for interference according to CLSI EP7-A2 Interference Testing in Clinical Chemistry; Approved Guideline - Second Edition. Bias is the difference in the results between the control sample (without the interferent) and the test sample (contains the interferent) expressed in percent. Bias exceeding $10 \%$ is considered interference.

<table><tr><td>Substance Tested</td><td>Substance Concentration</td><td colspan="2">Ammonia µg/dL [μmol/L].</td><td>Bias %</td><td></td></tr><tr><td>Hemoglobin (hemolysate)</td><td>75 mg/dL [0.05 mmol/L] 500 mg/dL [0.62 mmol/L]</td><td>85 426</td><td>[50] 250]</td><td>+12 +17</td><td rowspan="3"></td></tr><tr><td>Bilirubin</td><td>80 mg/dL [1026 µmol/L]</td><td>85</td><td>[50]</td><td>&lt;10</td></tr><tr><td>(unconjugated)</td><td></td><td>426</td><td>[250]</td><td>&lt;10</td></tr><tr><td>Bilirubin (conjugated)</td><td>60 mg/dL [1026 µmol/L] 80 mg/dL [1368 µmol/L]</td><td>85 426</td><td>[50] [250]</td><td></td><td>-16 &lt;10</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Lipemia</td><td>50 mg/dL [0.565 mmol/L]</td><td>85</td><td>[50]</td><td></td><td>+13</td></tr><tr><td>(ntralipid)</td><td>50 mg/dL [0.565 mmol/L]</td><td>426</td><td>[250]</td><td></td><td>&lt;10</td></tr></table>

See Limitations of Procedure for complete listing of substances that exceeded a bias of $10 \%$ .

Studies were also performed following CLSI EP7-A2 for Interference Testing of exogenous substances at ammonia concentrations of $8 5 \mu g / d L$ [50 µmol/L] and $4 2 6 \mu 9 / \alpha L$ [250 µmol/L] and were found not to interfere with the AMM method when present in plasma. Inaccuracies (biases) were all less than $10 \%$ See Dimension® AMM Instructions for Use for a full list of substances tested.

The AMM assay was evaluated for interference according to CLSI/NCCLS EP7-A2. Bias is the difference in the results between the control sample (without the interferent) and the test sample (contains the interferent) expressed in percent. Bias exceeding $10 \%$ is considered interference. Testing was performed at two levels of analyte concentration.

<table><tr><td rowspan=1 colspan=1>Analyte Test Level</td><td rowspan=1 colspan=2>85 μg/dL [50 μmol/L]</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Interferent</td><td rowspan=1 colspan=1>[Test] mg/dL</td><td rowspan=1 colspan=1>[Test] SlUnits</td><td rowspan=1 colspan=1>Bias(%)</td></tr><tr><td rowspan=1 colspan=1>Albumin</td><td rowspan=1 colspan=1>6 g/dL</td><td rowspan=1 colspan=1>60 g/L</td><td rowspan=1 colspan=1>49</td></tr><tr><td rowspan=1 colspan=1>Bilirubin(conjugated)</td><td rowspan=1 colspan=1>60mg/dL</td><td rowspan=1 colspan=1>.1026 μmol/L</td><td rowspan=1 colspan=1>-16</td></tr><tr><td rowspan=1 colspan=1>Cholesterol</td><td rowspan=1 colspan=1>503 mg/dL</td><td rowspan=1 colspan=1>13 mmol/L</td><td rowspan=1 colspan=1>65</td></tr><tr><td rowspan=1 colspan=1>Creatinine</td><td rowspan=1 colspan=1>30 mg/dL</td><td rowspan=1 colspan=1>2.65 mmol/L</td><td rowspan=1 colspan=1>34</td></tr><tr><td rowspan=1 colspan=1>Dextran 40</td><td rowspan=1 colspan=1>500 mg/dL</td><td rowspan=1 colspan=1>125 μmol/L</td><td rowspan=1 colspan=1>13</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>75 mg/dL</td><td rowspan=1 colspan=1>0.05 mmol/L(monomer)</td><td rowspan=1 colspan=1>12</td></tr><tr><td rowspan=1 colspan=1>Immunoglobulin G</td><td rowspan=1 colspan=1>5 g/dL</td><td rowspan=1 colspan=1>50 g/L</td><td rowspan=1 colspan=1>30</td></tr><tr><td rowspan=1 colspan=1>Lipemia (Intralipid)</td><td rowspan=1 colspan=1>50 mg/dL</td><td rowspan=1 colspan=1>0.5 g/L</td><td rowspan=1 colspan=1>13</td></tr><tr><td rowspan=1 colspan=1>Triglycerides</td><td rowspan=1 colspan=1>3000 mg/dL</td><td rowspan=1 colspan=1>33.9 mmol/L</td><td rowspan=1 colspan=1>*</td></tr><tr><td rowspan=1 colspan=1>Uric Acid</td><td rowspan=1 colspan=1>20 mg/dL</td><td rowspan=1 colspan=1>1.2 mmol/L</td><td rowspan=1 colspan=1>43</td></tr></table>

\*Tripped a test report message; therefore magnitude of the interference could not be determined.

<table><tr><td rowspan=1 colspan=1>Analyte Test Level</td><td rowspan=1 colspan=2>426 μg/dL [250 µmol/L]</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Interferent</td><td rowspan=1 colspan=1>[Test] mg/dL</td><td rowspan=1 colspan=1>[Test] S.I.Units</td><td rowspan=1 colspan=1>Bias(%)</td></tr><tr><td rowspan=1 colspan=1>Albumin</td><td rowspan=1 colspan=1>6 g/dL</td><td rowspan=1 colspan=1>60 g/L</td><td rowspan=1 colspan=1>15</td></tr><tr><td rowspan=1 colspan=1>Cholesterol</td><td rowspan=1 colspan=1>503 mg/dL</td><td rowspan=1 colspan=1>13 mmol/L</td><td rowspan=1 colspan=1>34</td></tr><tr><td rowspan=1 colspan=1>Dextran 40</td><td rowspan=1 colspan=1>3000 mg/dL</td><td rowspan=1 colspan=1>750 μmol/L</td><td rowspan=1 colspan=1>16</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>500 mg/dL</td><td rowspan=1 colspan=1>0.31 mmol/L</td><td rowspan=1 colspan=1>17</td></tr><tr><td rowspan=1 colspan=1>Uric Acid</td><td rowspan=1 colspan=1>20 mg/dL</td><td rowspan=1 colspan=1>1.2 mmol/L</td><td rowspan=1 colspan=1>17</td></tr></table>

For certain endogenous interferents which exceeded $10 \%$ bias, an aliquot of patient sample containing the potential interferent (test) was mixed with equal parts of a plasma pool containing approximately $8 5 \mu 9 / \mathsf { d L }$ $[ 5 0 ~ \mu \mathrm { m o l / L } ]$ ammonia (control). Test samples and control samples were processed and percent recovery calculated from expected and observed values. No significant interference was observed based on recovery within $10 \%$ of expected value.

<table><tr><td rowspan="2">Substance Tested</td><td colspan="2">Test Concentration</td><td colspan="2">AMM concentration</td></tr><tr><td>conventional</td><td>Sl unit</td><td>μg/dL</td><td>[μmol/L]</td></tr><tr><td>Albumin</td><td>5.4 g/dL</td><td>54 g/L</td><td>182</td><td>[107]</td></tr><tr><td>Cholesterol</td><td>364 mg/dL</td><td>9.7 μmol/L</td><td>232</td><td>[136]</td></tr><tr><td>Creatinine</td><td>21.1 mg/dL</td><td>1.87 mmol/L</td><td>233</td><td>[137]</td></tr><tr><td>Immunoglobulin G</td><td>3.4 g/dL</td><td>34 g/L</td><td>308</td><td>[181]</td></tr><tr><td>Triglyceride</td><td>1102 mg/dL</td><td>12.3 mmol/L</td><td>354</td><td>[208]</td></tr><tr><td>Uric Acid</td><td>9.3 mg/dL</td><td>0.6 mmol/L</td><td>196</td><td>[115]</td></tr></table>

# Limit of Blank, Limit of Determination and Limit of Quantitation

The Limit of Blank (LoB), Limit of Detection (LoD) and Limit of Quantitation (LoQ) was evaluated in accordance with CLSI EP17-A Protocols for Determination of Limits of Detection and Limits of Quantitation; Approved Guideline. Studies were performed on the Dimension clinical chemistry analyzer with the following results:

<table><tr><td rowspan=1 colspan=3>Dimension® Ammonia (AMM)</td></tr><tr><td rowspan=1 colspan=1>Limit</td><td rowspan=1 colspan=1>Protocol</td><td rowspan=1 colspan=1>Value</td></tr><tr><td rowspan=1 colspan=1>LoB</td><td rowspan=1 colspan=1>4 blank samples were testedfor 3 days, one run per day, 2replicates per run, 2 reagentlots, 1 instrument</td><td rowspan=1 colspan=1>4 µg/dL [2 µmol/L]</td></tr><tr><td rowspan=1 colspan=1>LoD</td><td rowspan=1 colspan=1>4 low level ammonia sampleswere tested for 3 days, onerun per day, 2 replicates perrun, 2 reagent lots, 1instrument</td><td rowspan=1 colspan=1>15 µg/dL [9 µmol/L]</td></tr><tr><td rowspan=1 colspan=1>LoQ</td><td rowspan=1 colspan=1>3 low level samples dilutedwith purified water were testedfor 3 days, one run per day, 3replicates per run, 2 reagentlots, 1 instrument</td><td rowspan=1 colspan=1>17 μg/dL [10 µmol/L]</td></tr></table>

These results support the claims of a LoB of 9 µg/dL [5 µmol/L], 17 µg/dL [10 µmol/L] for LoD and 17 µg/dL [10 µmol/L] for LoQ.

# Calibrator

Once the vial is punctured, assigned values are stable for 24 hours stored on the Dimension Vista® System. Once cap is removed, assigned values are stable for 30 days when recapped immediately after use and stored at $2 . 8 \%$ Do not use this vial on board the instrument.

The shelf life of the Dimension Vista® CHEM 3 CAL is 12 months.

1. Conclusion: The Dimension Vista® Ammonia (AMM) $F l e x ^ { \otimes }$ reagent cartridge assay and the associated Dimension Vista® Chemistry 3 Calibrator (CHEM 3 CAL) are substantially equivalent in principle and performance to the predicates, Dimension® Ammonia (AMON) assay and the Dimension Vista® Chemistry 3 Calibrator (CHEM 3 CAL) calibrator respectively.

March 7, 2013

Siemens Healthcare Diagnostics, Inc. c/o Rose T. Marinelli   
P.O. Box 6101   
500 GBC Drive, M/S 514   
Newark, DE 19702

Re: k123677 Trade/Device Name: Dimension Vista Ammonia Flex reagent cartridge (AMM) and Dimension Vista Chemistry 3 Calibrator (CHEM 3 CAL) Regulation Number: 21 CFR 862.1065 Regulation Name: Ammonia test system Regulatory Class: Class I, reserved Product Code: JIF, JIX Dated: January 31, 2013 Received: February 01, 2013

Dear Ms. Marinelli:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Courtney H. Lias, Ph.D.   
Director   
Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostics   
and Radiological Health   
Center for Devices and Radiological Health

Enclosure

# Indications for Use

510(k) Number (if known): k123677

# Device Name: Dimension Vista® Ammonia Flex® reagent cartridge (AMM)

Indications for Use:

The AMM method is an in vitro diagnostic test for the quantitative measurement of ammonia in human plasma (heparin or EDTA) on the Dimension Vista® System. Ammonia measurements are used in the diagnosis and treatment of severe liver disorders such as cirrhosis, hepatitis and Reye's syndrome

510(k) Number (if known): k123677

# Device Name: Dimension Vista® Chemistry 3 Calibrator (CHEM 3 CAL)

Indications for Use:

The CHEM 3 CAL is an in vitro diagnostic product for the calibration of Ammonia (AMM), Carbon Dioxide (C02) and Ethyl Alcohol (ETOH) methods on the Dimension Vis  System.

# Concurrence of CDRH, Office of In Vitro Diagnostics and Radiological Health (OIR)